<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03084692</url>
  </required_header>
  <id_info>
    <org_study_id>HREBA.CC-17-0049</org_study_id>
    <nct_id>NCT03084692</nct_id>
  </id_info>
  <brief_title>Therapeutic Yoga and Resistance Exercise for Lung Cancer</brief_title>
  <acronym>ASSURE</acronym>
  <official_title>Feasibility and Preliminary Efficacy of a Combined Therapeutic Yoga and Resistance Exercise Intervention for Individuals With Lung Cancer and Their Caregivers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alberta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alberta</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine the feasibility and preliminary efficacy of a
      combined therapeutic yoga and resistance exercise intervention for individuals with lung
      cancer and their caregivers. The investigators aim is to help reduce the fear of exercise by
      tailoring the program to meet the specific needs of the survivor with lung cancer. The
      investigators want to see whether individuals with lung cancer and their caregivers are
      interested in participating in this type of program, and if they are able to attend the
      intervention sessions and complete the program. The investigators also plan to study the
      preliminary effects of therapeutic yoga and resistance exercise on fitness outcomes for both
      individuals with lung cancer and their caregivers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To determine the feasibility of a combined therapeutic yoga and resistance exercise
      intervention for lung cancer survivors and their caregivers. A single group before and after
      intervention study design will be used for this pilot feasibility trial. Brochures and
      information about the study will be distributed at the Cross Cancer Institute, and interested
      individuals will be screened for eligibility. A convenient sampling technique will be used to
      recruit individuals with lung cancer and their caregiver. Participants deemed eligible to
      take part in the study will provide written informed consent to participate in the study and
      will undergo baseline testing. The intervention will be carried out over a period of 8 weeks.
      The feasibility outcomes will include eligibility rate, completion rate, adherence rate and
      adverse events. Dyspnea will be the primary self-reported outcome to be measured for
      individuals with lung cancer. The secondary outcomes will include fatigue, shoulder range of
      motion, chest expansion, and muscular strength. The outcome measures for the caregivers will
      include quality of life (QoL) and muscular strength.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 14, 2017</start_date>
  <completion_date type="Anticipated">June 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>A single group before and after intervention study design will be used for this pilot feasibility trial.</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Completion Rate</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>Completion rate is defined as the number of participants successfully completing the baseline assessment, intervention, and the post-intervention assessment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dyspnoea Visual Analogue Scale</measure>
    <time_frame>8 weeks</time_frame>
    <description>Visual Analogue Scale used to measure subjective breathlessness of a horizontal 10-cm line with phrases at both ends of the scale demonstrating minimum and maximum level of breathlessness.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dyspnoea-12</measure>
    <time_frame>8 weeks</time_frame>
    <description>The dyspnea-12 consists of 12 item scale to which patients respond about their general perception of their current state. It quantifies breathlessness using descriptions by patients of both physical and affective aspects of dyspnoea.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Assessment of Cancer Therapy: Fatigue Scale (FACT-F)</measure>
    <time_frame>8 weeks</time_frame>
    <description>The FACT-F was developed to measure fatigue in oncology patients with anemia. It has 13 items, which cover physical fatigue, functional fatigue, emotional fatigue, and social consequences of fatigue.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chest expansion (centimetres)</measure>
    <time_frame>8 weeks</time_frame>
    <description>The circumference of the chest is measured after an inspiration and an expiration using a tape at the level xiphisternum in standing position, using two different arm positions: hands on head and arms at the side.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Shoulder Range of Motion (degrees)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Active Flexion and Abduction will be measured using a handheld goniometer with the participant in a sitting position.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscular strength</measure>
    <time_frame>8 weeks</time_frame>
    <description>All participants, the individuals with lung cancer and their caregivers will perform a 1RM test before and after the 8-week intervention, to measure the changes in their muscle strength of upper extremity and lower extremity on a bench press, seated row, and a leg press.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary Function Testing</measure>
    <time_frame>8 weeks</time_frame>
    <description>The lung volumes and capacities will be measured using the spirometer in a sitting position. The forced expiratory volume in one second (fev1) and the forced vital capacity (fvc) will be measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CareGiver Oncology Quality of Life (CarGOQoL) questionnaire (Caregivers only)</measure>
    <time_frame>8 weeks</time_frame>
    <description>The CareGiver Oncology Quality of Life (CarGOQoL) questionnaire is a 29-item, multidimensional, self-administered questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chalder Fatigue Scale (Caregivers only)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Chalder Fatigue Scale is an 11 item scale to assess symptoms of fatigue such as tiredness, sleepiness, lack of energy, lack of strength in the muscles, difficulties in concentration and memory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence Rate</measure>
    <time_frame>up to 8 weeks</time_frame>
    <description>Attendance at exercise sessions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recruitment rate</measure>
    <time_frame>24 weeks</time_frame>
    <description>The number of participants agreeing to participate divided by the total number eligible</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Event</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>Incidence of serious and non-serious adverse events will be recorded</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Therapeutic Yoga and Resistance Exercise</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The individuals with lung cancer and their caregivers will participate in a combined intervention of yoga and resistance exercise for 8-week, two times/week. The dyad will attend a one-hour resistance exercise intervention at the start of the week and a one-hour yoga class with a break of one day between both interventions. The resistance exercise training will involve one-on-one personal exercise session, while the yoga intervention will be offered in a class setting. The participants will be allowed to make up for any missed resistance exercise session based on the available time. Pamphlets will be given demonstrating breathing exercises, meditation, postures, and core resistance exercises to facilitate programming.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Therapeutic Yoga and Resistance Exercise</intervention_name>
    <description>Combined Program of Yoga and Resistance Exercise</description>
    <arm_group_label>Therapeutic Yoga and Resistance Exercise</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of Primary Lung Cancer Stage I-IV (all stages)

          2. Any form of Lung cancer included: Small Cell Lung Cancer and Non-Small Cell Lung
             Cancer

          3. Age: 18 years or above

          4. Patients at any time point during treatment: ongoing treatment, completed treatment or
             recently diagnosed and about to start treatment

          5. Karnofsky Performance Status â‰¥ 50 (Appendix A)

          6. Life expectancy at least one year -

        Exclusion Criteria:

          1. Metastatic lung disease that would preclude safe exercise prescription

          2. Secondary Lung cancer due to metastasis from other parts of body

          3. Co-morbid conditions such as diabetes, congestive heart failure, dementia,
             cerebrovascular diseases.

          4. Individuals who would be unsafe to participate in an intervention program.

          5. Unable to provide consent in English

          6. Unable to complete either testing or intervention components (e.g. extended holiday)

        Caregiver eligibility: Caregivers will be screened using the PAR-Q + questionnaire and will
        be required to obtain approval from a family physician should any safety concerns be
        identified.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Margaret McNeely</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alberta</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Margaret L McNeely, PhD</last_name>
    <phone>780-248-1531</phone>
    <email>mmcneely@ualberta.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shreya Rewar, BSc PT</last_name>
    <phone>780-492-6007</phone>
    <email>rewar@ualberta.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alberta/ Cross Cancer Institute</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2G4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margaret McNeely, PhD</last_name>
      <phone>780-248-1531</phone>
      <email>mmcneely@ualberta.ca</email>
    </contact>
    <investigator>
      <last_name>Margaret L. McNeely, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 14, 2017</study_first_submitted>
  <study_first_submitted_qc>March 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 21, 2017</study_first_posted>
  <last_update_submitted>April 9, 2018</last_update_submitted>
  <last_update_submitted_qc>April 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>caregiver</keyword>
  <keyword>lung cancer</keyword>
  <keyword>yoga</keyword>
  <keyword>resistance exercise</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Undecided at this time.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

